author-photo

Andrew Peter Thomas

AstraZeneca

48

Papers

2223

Citations

Citation Trend

Filter By

Papers (35) Sort By

Journal Conference Others

Targeting a Novel KRAS Binding Site: Application of One-Component Stapling of Small (5-6-mer) Peptides.

2021 Journal of Medicinal Chemistry
Show All
- Source
- Cite
- Save
Citations (0)
Selective CRAF Inhibition Elicits Transactivation.

2021 Journal of the American Chemical Society
Show All
- Source
- Cite
- Save
Citations (1)
A High-Throughput Screening Triage Workflow to Authenticate a Novel Series of PFKFB3 Inhibitors

2018
Show All
- Source
- Cite
- Save
Citations (6)
human PFKFB3 in complex with a pyrrolopyrimidone compound

2016
Show All
- Source
- Cite
- Save
Citations (0)
Abstract C135: AZ’4425 is a potent, selective, and orally bio-available progesterone receptor antagonist that has shown anti-tumor activity and inhibition of cancer stem cell proliferation.

2013 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (0)
Abstract 3912: The discovery of AZD4547: An orally bioavailable, potent and selective N-(5-Pyrazolyl)benzamide FGFR1-3 inhibitor

2012 Cancer Research
Show All
- Source
- Cite
- Save
Citations (2)
Protein-Ligand Crystal Structures Can Guide the Design of Selective Inhibitors of the FGFR Tyrosine Kinase.

2012 Journal of Medicinal Chemistry
Show All
- Source
- Cite
- Save
Citations (36)
AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family

2012 Cancer Research
Show All
- Source
- Cite
- Save
Citations (374)
Abstract 3568: Characterization of AZD4547: An orally bioavailable, potent and selective inhibitor of FGFR tyrosine kinases 1, 2 and 3

2011 Cancer Research
Show All
- Source
- Cite
- Save
Citations (8)
Gene Copy Number Aberrations Are Associated with Survival in Histologic Subgroups of Non-small Cell Lung Cancer

2011 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (40)